LivaNova Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance
LivaNova (LIVN) reported strong third-quarter results for 2026, with total revenue reaching $393.1 million, a 10% increase on a constant-currency basis. The growth was driven by robust demand in both the cardiopulmonary and neuromodulation segments, specifically through Essenz perfusion systems and increased patient volumes in the U.S. and Europe. Following these results, the company raised its full-year revenue guidance to 9%–10% and adjusted diluted EPS guidance to $4.40–$4.50. Financial health remains stable as the company reduced total debt to $299.1 million through early repayment of a term facility, despite increased capital expenditures aimed at manufacturing scale-up and IT infrastructure.
Tickers: $LIVN
Topics: cardiopulmonary technology guidance raise neuromodulation revenue growth